5 Stocks Pushing The Health Care Sector Higher
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our modelTwo out of the three major indices are trading lower today with the Dow Jones Industrial Average (^DJI) trading up 15 points (0.1%) at 12,980 as of Tuesday, Dec. 4, 2012, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,319 issues advancing vs. 1,553 declining with 162 unchanged.The Health Care sector currently sits down 0.3% versus the S&P 500, which is down 0.1%. Top gainers within the sector include Edwards Life (EW), up 4.5%, Shire (SHPG), up 2.7%, Valeant Pharmaceuticals International (VRX), up 1.1%, Abbott Laboratories (ABT), up 0.8% and GlaxoSmithKline (GSK), up 0.8%.TheStreet Ratings group would like to highlight 5 stocks pushing the sector higher today:5. Teva Pharmaceutical Industries (TEVA) is one of the companies pushing the Health Care sector higher today. As of noon trading, Teva Pharmaceutical Industries is up $0.70 (1.7%) to $41.25 on average volume Thus far, 2.0 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3.1 million shares. The stock has ranged in price between $40.37-$41.32 after having opened the day at $40.37 as compared to the previous trading day's close of $40.55. Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $35.0 billion and is part of the drugs industry. The company has a P/E ratio of 10.9, below the S&P 500 P/E ratio of 17.7. Shares are down 0.0% year to date as of the close of trading on Monday. Currently there are 16 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 8 rate it a hold.TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Teva Pharmaceutical Industries Ratings Report now.EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass
Latest Headlines about JNJ
-
Johnson & Johnson Gets Key Cancer Drug With Aragon Buy
11:15AM 06/18/13
-
Buy-Rated Dow Components Slip To Ten
08:00AM 06/18/13
-
J&J Buy of Aragon Deals a Blow to Medivation
09:57AM 06/17/13
-
5 Big Trades for a Ping-Pong Market
06:51AM 06/13/13
-
Some Top Funds Are Dumping Bonds
08:43AM 06/12/13
-
New Data Improves Sales Outlook For Celgene's Apremilast
08:02AM 06/12/13
-
5 Big Stocks to Sell Now
09:54AM 05/30/13
Latest from TheStreet Wire
-
Randgold Resources Ltd (GOLD): Today's Featured Basic Materials Laggard
05:01PM 06/18/13
-
Pinnacle West Capital Corporation (PNW): Today's Featured Utilities Laggard
05:01PM 06/18/13
-
Saks Incorporated (SKS): Today's Featured Retail Laggard
05:01PM 06/18/13
-
Catamaran Corp (CTRX): Today's Featured Computer Software & Services Laggard
05:01PM 06/18/13
-
Leucadia National Corporation (LUK): Today's Featured Food & Beverage Laggard
05:01PM 06/18/13
-
Clearwire Corp (CLWR): Today's Featured Telecommunications Laggard
05:01PM 06/18/13
-
Infosys Ltd (INFY): Today's Featured Technology Laggard
05:01PM 06/18/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
